Men rarely give their prostate a second thought until something goes wrong. What causes an enlarged prostate, or benign prostatic hyperplasia (BPH), comes down to a mix of hormonal shifts, cellular changes, and metabolic health. Age is the single biggest factor, but it’s far from the only one.<\/p>\n\n\n\n
An enlarged prostate forms when cells inside the gland multiply faster than they die off, slowly expanding a structure that wraps directly around the urethra. The male hormones dihydrotestosterone (DHT) and testosterone are the primary drivers of that ongoing cell growth. Men over 50 are the demographic most commonly affected, though the cellular groundwork starts much earlier.<\/p>\n\n\n\n
Understanding prostate anatomy<\/a> helps here: the gland sits just below the bladder and encircles the urethra, so even modest growth can restrict urine flow noticeably. A closer look at prostate gland function<\/a> makes clear why the location matters, any swelling presses inward on the urinary channel rather than outward into open tissue.<\/p>\n\n\n\n This article breaks down the root causes in plain terms. You can cross-reference symptoms alongside the mechanisms described here with a broader clinical overview of BPH signs and treatment<\/a>, and what causes an enlarged prostate<\/a> has been studied extensively. The short answer is that DHT and aging work together, with inflammation and metabolic factors making both worse.<\/p>\n\n\n\n Aging changes the hormonal environment inside the prostate in ways that favor cell growth. Testosterone production gradually declines from around age 40 onward, but DHT levels inside the prostate tissue itself stay relatively stable, or even rise, because the enzyme 5-alpha-reductase keeps converting available testosterone into DHT locally.<\/p>\n\n\n\n The result is a gland that receives a steady growth signal even as overall hormone levels fall.<\/p>\n\n\n\n DHT binds to androgen receptors in prostate cells and signals them to grow and divide. It’s roughly five times more potent than testosterone at those receptors. When the balance between cell proliferation and natural cell death (apoptosis) tips toward proliferation, tissue accumulates and the gland enlarges. Medications called 5-alpha-reductase inhibitors work precisely by blocking this conversion step.<\/p>\n\n\n\n Most BPH discussions focus on testosterone and DHT alone, but estrogen plays an underreported role. As men age, circulating testosterone falls while estradiol (a form of estrogen) stays relatively sustained in prostate tissue. That shifting testosterone-to-estrogen ratio is thought to make prostate cells more sensitive to DHT-driven growth signals, though the evidence here is largely mechanistic and observational rather than from large randomized trials.<\/p>\n\n\n\n A comprehensive review published in 2025<\/a> found that genetic factors account for roughly 60% of BPH’s phenotypic variation, confirming that hormonal changes alone don’t tell the full story. The interplay of hormones and inherited susceptibility shapes how aggressively the gland responds to those shifts. A global burden analysis<\/a> tracking BPH from 1990 to 2021 showed prevalent cases nearly doubled over three decades, a trend consistent with aging populations but also with rising metabolic risk.<\/p>\n\n\n\n For a deeper explanation of DHT’s mechanics, everything you need to know about DHT<\/a> covers the hormone’s role in prostate growth.<\/p>\n\n\n\n Subtle cellular growth inside the prostate often begins in a man’s 40s, long before any symptoms appear. By the 60s, histological BPH – enlargement visible on tissue examination – is present in 50 to 60% of men. That figure climbs to 80 to 90% in men over 70, according to NCBI StatPearls<\/a>. So while symptoms might only surface at 55 or 60, the biological process started quietly a decade or more earlier.<\/p>\n\n\n\n DHT maintains what researchers call a balance between proliferative and apoptotic processes in prostate tissue. With age, that equilibrium shifts. DHT continues to stimulate growth signals while the mechanisms that normally clear aging cells slow down. Over years, this imbalance accumulates, not as cancer (prostate cancer is a separate process), but as a steady expansion of glandular and stromal tissue.<\/p>\n\n\n\n Chronic low-grade inflammation within prostate tissue is now recognized as an important contributor to glandular overgrowth, and it’s a mechanism that most content on this topic skips entirely. This is distinct from prostatitis (an active infection or acute inflammation of the prostate); it’s a subtler, persistent inflammatory state.<\/p>\n\n\n\n Research published in the Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira<\/a> identified immune-inflammatory pathways – including the cytokine IL-17 – as important mediators in BPH development. Pro-inflammatory molecules appear to alter the local tissue environment in ways that encourage cell proliferation. Oxidative stress and chronic inflammation<\/a> in prostate tissue compound these effects, disrupting the cellular balance between growth and programmed cell death. A cross-sectional ultrasound study<\/a> examining validated BPH risk factors similarly found inflammatory and metabolic markers clustering among men with larger prostate volumes.<\/p>\n\n\n\n The inflammation-BPH connection is also supported by burden-of-disease data showing the condition is strongly associated with immune aging and lipid disorders tied to metabolic syndrome. A body carrying chronic inflammation from visceral fat, poor diet, or metabolic disease creates a prostate environment more prone to overgrowth. The evidence is largely observational and mechanistic at this stage, but it’s strong enough that inflammation management is increasingly part of how urologists think about BPH prevention.<\/p>\n\n\n\n No single factor causes BPH. What causes an enlarged prostate in any individual man is usually a combination of age, genetics, hormonal shifts, and lifestyle. A 2025 analysis found that globally, BPH prevalent cases grew 122%<\/a> between 1990 and 2021, reaching roughly 112.5 million cases worldwide, a surge caused not just by aging populations but by rising rates of metabolic disease.<\/p>\n\n\n\n Around 50% of men over 50 develop BPH<\/a>, with that proportion rising sharply through the 60s and 70s. For a practical breakdown of which factors carry the most weight, BPH risk factors<\/a> covers the evidence in more depth.<\/p>\n\n\n\n On ethnicity:<\/strong> Current evidence suggests Black men tend to develop BPH earlier and with more severe symptoms, while Asian men historically show lower rates, though access-to-care differences make these patterns difficult to interpret definitively. The mechanisms aren’t fully understood, and research is ongoing.<\/p>\n\n\n\n Age is the dominant non-modifiable risk factor. Having a father or brother with BPH roughly doubles your own risk, consistent with the high heritability estimates from family and twin studies. And a pathophysiology review<\/a> confirmed that genetic predisposition shapes both when the prostate starts growing and how quickly symptoms emerge.<\/p>\n\n\n\n Sedentary behavior, a high-fat diet, smoking, and heavy alcohol use are all associated with higher BPH risk. These aren’t fringe observations, they reflect the same metabolic pathways that make the prostate more vulnerable to inflammation and hormonal imbalance.<\/p>\n\n\n\n This is where metabolic health and prostate health overlap most clearly. Obesity raises fatty acid levels that activate pro-inflammatory cytokines, directly altering the prostatic environment. Hyperinsulinemia<\/a>, high circulating insulin, common in insulin resistance, stimulates growth factor pathways in prostate tissue. Men with metabolic syndrome<\/a>, the cluster of high blood pressure, high blood sugar, central obesity, and abnormal cholesterol, carry a significantly elevated risk of incident BPH, and cardiovascular disease risk factors<\/a> such as dyslipidemia and hypertension appear to act through shared inflammatory pathways that also drive prostate overgrowth. Signs of insulin resistance<\/a> are worth discussing with your doctor if you’re concerned about long-term prostate risk.<\/p>\n\n\n\n Yes, with caveats. Regular moderate physical activity is associated with lower BPH risk and less severe urinary symptoms in observational studies. The likely mechanism is reduced insulin resistance, lower circulating inflammatory markers, and improved hormone metabolism through consistent exercise<\/a>. But it’s a modest protective effect, exercise is one factor in a much larger picture.<\/p>\n\n\n\n Not every set of urinary symptoms means the prostate is enlarged. Getting to the right diagnosis matters, because the causes and treatments differ significantly.<\/p>\n\n\n\n Prostatitis (inflammation or infection of the prostate) can produce urgency, frequency, pelvic pain, and difficulty urinating that closely resembles BPH. But prostatitis often affects younger men and frequently involves fever or pain that BPH doesn’t. Urinary tract infections in men<\/a> can also trigger similar symptoms; conditions like bladder stones<\/a> or urinary tract stones<\/a> – sometimes a downstream consequence of BPH itself – can create their own overlapping symptom pattern.<\/p>\n\n\n\n Both can cause urinary obstruction, and both become more common with age. But they’re separate conditions with different biology. BPH grows in the central zone of the prostate and is non-malignant. Prostate cancer typically starts in the peripheral zone and can spread. Overlapping symptoms are common; a PSA test and, if indicated, a biopsy are how doctors distinguish them. Don’t assume urinary symptoms are just BPH, get evaluated.<\/p>\n\n\n\n BPH isn’t a sudden event. It’s a slow accumulation measured in years or decades, and understanding the timeline helps explain why symptoms often catch men off guard.<\/p>\n\n\n\n The distinction between hypertrophy and hyperplasia<\/a> is worth noting here: hypertrophy means existing cells get larger, while hyperplasia means the number of cells increases. BPH is primarily hyperplasia, more cells, not just bigger ones.<\/p>\n\n\n\n A 2025 population-based study covering 1990 to 2021<\/a> estimated the global lifetime risk of BPH from age 40 at 27.29%, with variation by region and socioeconomic status. According to NCBI StatPearls<\/a>, the condition rarely produces symptoms in the 40s, even when microscopic growth is already underway.<\/p>\n\n\n\nThe role of aging and hormones<\/strong><\/h3>\n\n\n\n
Why DHT matters<\/strong><\/h3>\n\n\n\n
How Hormone Balance Shifts as Men Age<\/strong><\/h2>\n\n\n\n
At what age does prostate growth typically begin?<\/strong><\/h3>\n\n\n\n
The cellular mechanism behind DHT-driven prostate growth<\/strong><\/h3>\n\n\n\n
How Inflammation Contributes to Prostate Enlargement<\/strong><\/h2>\n\n\n\n
Risk Factors That Increase Your Likelihood<\/strong><\/h2>\n\n\n\n
Age and family history<\/strong><\/h3>\n\n\n\n
Lifestyle and metabolic factors<\/strong><\/h3>\n\n\n\n
How obesity, diabetes, and heart disease raise BPH risk<\/strong><\/h3>\n\n\n\n
Does exercise reduce the risk of prostate enlargement?<\/strong><\/h3>\n\n\n\n
Other Conditions That Mimic Prostate Enlargement<\/strong><\/h2>\n\n\n\n
Prostatitis and infection<\/strong><\/h3>\n\n\n\n
Prostate cancer vs. BPH<\/strong><\/h3>\n\n\n\n
How Enlarged Prostate Develops Over Time<\/strong><\/h2>\n\n\n\n
What happens to the prostate with age<\/strong><\/h3>\n\n\n\n